VYNE Therapeutics (VYNE) Accounts Payables (2016 - 2026)

VYNE Therapeutics' Accounts Payables history runs 11 years deep, the most recent figure standing at $261000.0 for Q1 2026.

• Quarterly Accounts Payables fell 92.61% year-over-year to $261000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $261000.0 (down 92.61% YoY) and the FY2025 annual result came in at $1.0 million, down 61.54% from the prior year.
• Accounts Payables was $261000.0 for Q1 2026 at VYNE Therapeutics, down from $1.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.5 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
• A 5-year average of $2.2 million and a median of $2.3 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables surged 456.7% — and 2026, when it slumped 92.61%.
• VYNE Therapeutics' Accounts Payables stood at $2.4 million in 2022, then plunged by 30.47% to $1.7 million in 2023, then soared by 63.17% to $2.7 million in 2024, then sank by 61.54% to $1.0 million in 2025, then sank by 74.93% to $261000.0 in 2026.
• Business Quant data shows VYNE's Accounts Payables at $261000.0 in Q1 2026, $1.0 million in Q4 2025, and $1.4 million in Q2 2025.